Activaero Closes a [euro] 10.7 Million ($16 million) Series A Financing.GEMUENDEN, Germany & DUBLIN, Ohio Dublin is a city in Delaware, Franklin, and Union counties in the U.S. state of Ohio. The population was 31,392 at the 2000 census. In 2006, the population was estimated to be 36,565[1], and Dublin continues to be one of the fastest-growing suburbs of Columbus. -- Activaero GmbH, the leading company in the field of controlled breathing technologies for inhaled in·hale v. in·haled, in·hal·ing, in·hales v.tr. 1. To draw (air or smoke, for example) into the lungs by breathing; inspire. 2. therapeutic agents, announced today the closing of a Series A financing totalling [euro] 10.7 Million ($16 million). The international consortium was led by BioMedPartners AG (advising BioMedInvest LP II) and included VI Partners AG, Abalis Finance AG and Vesalius Biocapital I SICAR S.A.. The transaction was advised by MedVenture Partners GmbH. The financing enables the Company to further develop its proprietary inhalation inhalation /in·ha·la·tion/ (in?hah-la´shun) 1. the drawing of air or other substances into the lungs.inhala´tional 2. the drawing of an aerosolized drug into the lungs with the breath. 3. devices and strengthen business development activities for Activaero's leading controlled inhalation technologies. "Securing venture capital support for Activaero is important for our strategy to further increase visibility and awareness within the pharmaceutical industry and provide superior products and technologies to our collaboration partners. Therefore, we are delighted to have closed this financing round with such a consortium of leading Life Sciences investors," said Gerhard Scheuch, Chief Executive Officer of Activaero. "The development and commercialization of our products and technology is now securely funded going forward." "Activaero has an outstanding expertise and reputation in the field of controlled inhalation. We are convinced that the strength of the unique technology combined with the experience of the team makes Activaero a very attractive investment and we are glad to be able to support Activaero in its further development and commercialization stages," commented Gerhard Ries, General Partner at BioMedPartners. At the same time, Gerhard Ries of BioMedPartners, Arnd Kaltofen of VI Partners, Jean-Marie Luechinger of Abalis Finance, Christian Schneider of Vesalius Biocapital Partners and John Patton There are several persons named John Patton:
The board of directors that represents stakeholders in the governance of the corporation. . *** About Activaero GmbH Activaero is the leading company in the field of controlled breathing technologies for inhaled therapeutic agents. With stand alone inhalation products and inhalation systems available for clinical trials and marketing partnerships, Activaero's technologies allow for the most precise and efficient patient-tailored pulmonary delivery. Activaero currently has two products on the market, AKITA[R], a patient-tailored controlled breathing system with a smartcard that records the patient dosing parameters, and Watchhaler[TM], a hand held delivery system tailored specifically to children. The Company also has available a range of technologies ideal for the controlled delivery of inhaled therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. in the clinical trial setting and tailored to specific partnerships (AKITA2[R], LimiX[TM]). Finally, Activaero works with partners on a consultancy basis in the development of ideal inhaled delivery systems and the logistics in clinical trials. Activaero's technological approach has been validated repeatedly in the clinical setting. The Company is privately held and located in Gemunden (Wohra) and Munich in Germany and Dublin, Ohio in the USA. About Abalis Finance AG Abalis Finance AG is an independent Swiss Holding Company focused on financing market growth of successful companies in the field of Pharmaceuticals, Life Science and Med Tech The company takes participations but grants under certain circumstances credits as well. Along with the financial participation Abalis plays an active role in the companies it supports by sharing its knowledge. The management has the longstanding successful international experience in the development and marketing of originator as well as generic pharmaceuticals. Abalis Finance AG also owns and operates Abalis Pharma AG which is active in the development, marketing and licensing of value added Value Added The enhancement a company gives its product or service before offering the product to customers. Notes: This can either increase the products price or value. pharmaceutical product with a focus is on novel patentable solutions for solid dosage forms A dosage form is the physical form of a dose of medication, such as a capsule or injection. The route of administration is dependent on the dosage form of a given drug. . About BioMedPartners AG BioMedPartners AG is a leading independent European venture capital firm, providing private equity and mezzanine financing Mezzanine Financing A hybrid of debt and equity financing. Mezzanine financing is typically used to finance the expansion of existing companies, and it is basically debt capital that gives the lender the rights to convert to an ownership or equity interest in the company if the to early- to mid-stage healthcare and Life Sciences companies. Since 2003, BioMedPartners has invested in more than 30 highly innovative companies, of which five have already either successfully completed an IPO (Initial Public Offering) The first time a company offers shares of stock to the public. While not a computer term per se, many founders, employees and insiders of computer companies have found this acronym more exciting than any tech term they ever heard. (Arpida AG, Santhera Pharmaceuticals AG) or have been acquired by leading pharma companies (ESBATech AG, Glycart Biotechnology AG, Thommen Medical AG). Recently, BioMedPartners has announced the closing of its second BioMedInvest fund (BioMedInvest LP II) with a capital of around CHF CHF In currencies, this is the abbreviation for the Swiss Franc. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 100 million. With more than CHF 250 million in capital under management and a strong team of experienced specialists and industry experts as well as an extensive scientific and financial network, BioMedPartners has established itself as one of the leading early-stage healthcare investors in Europe. About Vesalius Biocapital Partners sarl Vesalius Biocapital Partners is a European venture capital firm that focuses on the creation and growth of pan-European early-stage life science companies. The managed Vesalius Biocapital funds invest in areas with a high unmet un·met adj. Not satisfied or fulfilled: unmet demands. medical need and a significant profit potential: new therapeutics, cutting-edge medical devices, innovative drug delivery technologies and diagnostic tests and instruments with a high utility level. The expertise of the team ranges from extensive investment and exit experience to operational experience in general management, business development, product development, IP, and finance of start-ups and more mature life science companies. Furthermore, individual team members have in-depth technical insights and competitive scouting scouting: see Boy Scouts; Girl Scouts. scouting Activities of various national and worldwide organizations for youth aimed at developing character, citizenship, and individual skills. Scouting began when Robert S. experience in the life science sector. For more information please see www.vesaliusbiocapital.com About VI Partners AG VI Partners is a Swiss venture capital firm that supports university spin-offs as well as other promising start-up companies start-up company A new business. with capital, coaching and networks. Via the current "Venture Incubator incubator, apparatus for the maintenance of controlled conditions in which eggs can be hatched artificially. Incubator houses with double walls of mud, a fireroom, and several compartments each holding about 6,000 hens' eggs were developed in ancient times; the " fund VI Partners invests "smart money" to develop promising technology-based ideas for products and services into successful businesses. For additional information please visit: www.vipartners.ch |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion